Medtronic plc. (NYSE:MDT)‘s stock had its “neutral” rating reiterated by stock analysts at BTIG Research in a research note issued on Monday.

A number of other equities research analysts have also issued reports on the stock. Vetr lowered shares of Medtronic plc. from a “hold” rating to a “sell” rating and set a $78.50 price target on the stock. in a report on Wednesday, March 1st. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $87.00 price target (up previously from $84.00) on shares of Medtronic plc. in a report on Thursday, February 23rd. Zacks Investment Research upgraded shares of Medtronic plc. from a “sell” rating to a “hold” rating in a report on Thursday, February 23rd. Leerink Swann boosted their price target on shares of Medtronic plc. from $80.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, February 23rd. Finally, Wedbush restated a “neutral” rating and set a $85.00 price target on shares of Medtronic plc. in a report on Wednesday, February 22nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and sixteen have issued a buy rating to the company’s stock. Medtronic plc. has a consensus rating of “Buy” and an average target price of $87.57.

Analyst Recommendations for Medtronic plc. (NYSE:MDT)

Medtronic plc. (NYSE:MDT) traded down 0.99% during trading on Monday, reaching $81.42. The company’s stock had a trading volume of 4,423,782 shares. Medtronic plc. has a 52-week low of $69.35 and a 52-week high of $89.27. The firm has a market capitalization of $111.45 billion, a price-to-earnings ratio of 28.74 and a beta of 0.97. The stock’s 50-day moving average is $79.29 and its 200 day moving average is $79.49.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/medtronic-plc-s-mdt-neutral-rating-reaffirmed-at-btig-research.html

Medtronic plc. (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 21st. The medical technology company reported $1.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.01. Medtronic plc. had a net margin of 14.63% and a return on equity of 12.36%. The business had revenue of $7.28 billion for the quarter, compared to analyst estimates of $7.22 billion. During the same quarter in the previous year, the business earned $1.06 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. On average, analysts predict that Medtronic plc. will post $4.58 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 13th. Investors of record on Friday, March 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 2.11%. The ex-dividend date of this dividend is Wednesday, March 22nd. Medtronic plc.’s dividend payout ratio is currently 57.14%.

Your IP Address:

In related news, EVP Hooman Hakami sold 52,316 shares of the company’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $82.33, for a total transaction of $4,307,176.28. Following the completion of the sale, the executive vice president now directly owns 73,800 shares of the company’s stock, valued at approximately $6,075,954. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Omar Ishrak sold 95,000 shares of the company’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $82.82, for a total transaction of $7,867,900.00. Following the sale, the chief executive officer now directly owns 645,616 shares of the company’s stock, valued at $53,469,917.12. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Fisher Asset Management LLC boosted its position in Medtronic plc. by 4.9% in the third quarter. Fisher Asset Management LLC now owns 4,949 shares of the medical technology company’s stock valued at $428,000 after buying an additional 233 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Medtronic plc. by 43.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 300,418 shares of the medical technology company’s stock valued at $25,956,000 after buying an additional 90,433 shares during the last quarter. Kelman Lazarov Inc. boosted its position in Medtronic plc. by 8.2% in the third quarter. Kelman Lazarov Inc. now owns 1,642 shares of the medical technology company’s stock valued at $141,000 after buying an additional 125 shares during the last quarter. Stillwater Capital Advisors LLC boosted its position in Medtronic plc. by 1.1% in the third quarter. Stillwater Capital Advisors LLC now owns 114,096 shares of the medical technology company’s stock valued at $9,858,000 after buying an additional 1,257 shares during the last quarter. Finally, Lawson Kroeker Investment Management Inc. NE boosted its position in Medtronic plc. by 3.7% in the third quarter. Lawson Kroeker Investment Management Inc. NE now owns 9,818 shares of the medical technology company’s stock valued at $848,000 after buying an additional 350 shares during the last quarter. Hedge funds and other institutional investors own 82.71% of the company’s stock.

Medtronic plc. Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

5 Day Chart for NYSE:MDT

Receive News & Ratings for Medtronic plc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic plc. and related companies with MarketBeat.com's FREE daily email newsletter.